Furthermore, in patients with untreated EGFRM+ advanced NSCLC from the phase III FLAURA study, osimertinib, in keeping with its higher CNS penetrance, demonstrated superior CNS efficacy and reduced risk of CNS progression when compared with SOC first-line EGFR-TKIs [26]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.